GIVAUDAN SA/ADR (OTCMKTS:GVDNY) Rating Reiterated by UBS Group

Share on StockTwits

GIVAUDAN SA/ADR (OTCMKTS:GVDNY)‘s stock had its “buy” rating reaffirmed by UBS Group in a report issued on Wednesday, The Fly reports.

GVDNY has been the subject of several other research reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of GIVAUDAN SA/ADR in a research note on Monday. ValuEngine raised shares of GIVAUDAN SA/ADR from a “sell” rating to a “hold” rating in a research report on Thursday, April 2nd. Baader Bank reissued a “buy” rating on shares of GIVAUDAN SA/ADR in a report on Monday, April 6th. Deutsche Bank restated a “hold” rating on shares of GIVAUDAN SA/ADR in a research report on Wednesday, July 1st. Finally, Credit Suisse Group reaffirmed an “underperform” rating on shares of GIVAUDAN SA/ADR in a research report on Monday. Four analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. GIVAUDAN SA/ADR presently has an average rating of “Hold”.

OTCMKTS:GVDNY opened at $76.07 on Wednesday. GIVAUDAN SA/ADR has a 1-year low of $51.80 and a 1-year high of $76.91. The business’s fifty day moving average price is $72.16 and its 200 day moving average price is $66.32.

About GIVAUDAN SA/ADR

Givaudan SA, together with its subsidiaries, manufactures and sells fragrance and flavor products to the food, beverage, consumer goods, and fragrance and cosmetics industries worldwide. The company operates through two divisions, Fragrance and Flavour. The Fragrance division provides fragrance ingredients and active beauty products; fine fragrances; and fragrances for use in fabric and personal care, skin and hair care, household, and oral care products.

Recommended Story: Why do commodities matter?

The Fly

Analyst Recommendations for GIVAUDAN SA/ADR (OTCMKTS:GVDNY)

Receive News & Ratings for GIVAUDAN SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GIVAUDAN SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.